TRANSTHERA-B (02617) surged nearly 14%, rising 13.85% to HKD 166.1 by the time of writing, with a trading volume of HKD 112 million. The company recently announced that the exploratory Phase 2 clinical results of its core product, tinengotinib, for cholangiocarcinoma conducted in the U.S., were published in *The Lancet Gastroenterology & Hepatology* (impact factor: 38.6). Researchers from the University of Texas MD Anderson Cancer Center commented, "We are seeking next-generation FGFR2 inhibitors for resistant cases. Tinengotinib, as a next-generation FGFR inhibitor, targets FGFR through a unique mechanism. In this Phase 2 study, tinengotinib demonstrated durable responses and prolonged survival in cholangiocarcinoma patients. These compelling data support initiating a Phase 3 registration trial." Tinengotinib is an internally developed, multi-target small-molecule kinase inhibitor in the registration-stage clinical phase, exerting anti-tumor effects by targeting tumor cells and improving the tumor microenvironment. Currently, tinengotinib has undergone multiple clinical trials in China and the U.S. for solid tumors such as cholangiocarcinoma, prostate cancer, and breast cancer. It has received FDA designations for cholangiocarcinoma, including Orphan Drug Designation (ODD) and Fast Track status, as well as Breakthrough Therapy and Priority Review approvals from China's NMPA. The EMA has also granted it Orphan Drug Designation for biliary tract cancer.